主页 > 生命科学 >
【bio-news】减肥药物可能有效，但决不神奇
Email Print Normal font Large font October 18, 2006 - 1:44PM
A new anti-obesity drug which could soon be available in Australia has been heralded as a better weight stripper than others already on the market.
The drug, known generically as rimonabant, has been on sale in Europe since July and approval in Australia and the US is pending.
Marketed as Acomplia, it works in a new way, suppressing the appetite by targeting the brain cells involved in the "munchies" familiar to marijuana users.
A Brazilian review of four randomised controlled trials, found that rimonabant does help people lose weight and also lowers cardiac risk factors.
"After one year of use (the drug) produces modest weight loss of approximately five per cent," said lead researcher Cintia Curioni, at the State University of Rio de Janeiro.
"Compared with placebo, a 20-milligram pill produced a 4.9kg greater reduction in body weight in trials with one-year results."
The work, published in US journal The Cochrane Library, found the drug induced greater weight loss than both orlistat, marketed as Xenical, and silbutramine, known as Reductil.
However the rimonabant results "probably represent a best-case scenario" because all four trials were funded by manufacturer Sanofi.
Obesity expert professor Gary Wittert, head of the School of Medicine at the University of Adelaide, said the drug had shown encouraging results in the international trial of 30 Melbourne patients he supervised.
However, he cautioned against comparing the three treatments, saying they all worked very differently and had various side effects.
Prof Wittert also warned that rimonabant was not a magic bullet for obesity.
"This is not a drug for cosmetic outcomes that you take because you want to look better in a dress or in a tuxedo," the specialist said.
"It's a drug to normalise metabolism that has, as an added benefit, weight loss. The public must be very, very clear about that."
The review of US, Canadian and European trials compared rimonabant at two dosages and with a placebo in 6,625 participants - all overweight or obese adults.
Reviewers found that only the higher dose, 20 milligrams, had significant impact on weight, waist circumference, cholesterol levels and blood pressure.
But this dose was more likely to bring on side effects, including nausea, dizziness and depression, than both the lower dose and placebo.
Sanofi has applied to the Therapeutic Goods Administration to sell the drug here, with a decision expected early next year. 认领，交稿
Weight loss drug effective but not magic
减肥药有效，但决不神奇
October 18, 2006 - 1:44PM
A new anti-obesity drug which could soon be available in Australia has been heralded as a better weight stripper than others already on the market.
一种很快将在澳大利亚上市的减肥药，已被预言减肥效果要好过市面上的其他药物。
The drug, known generically as rimonabant, has been on sale in Europe since July and approval in Australia and the US is pending.
这种药物，俗称rimonabant，7月已在欧洲上市销售，在澳大利亚和美国的审批目前还悬而未决。
Marketed as Acomplia, it works in a new way, suppressing the appetite by targeting the brain cells involved in the "munchies" familiar to marijuana users.
该药的商品名为Acomplia，它的作用途径很新颖，即以参与类似于大麻吸食者的那种“想吃的欲望”的那些脑细胞为靶点，来抑制食欲。
A Brazilian review of four randomised controlled trials, found that rimonabant does help people lose weight and also lowers cardiac risk factors.
一篇来自巴西的，对四项随机化、受控试验的评论文章称，rimonabant不但有助于减肥，还能降低心脏病风险因子。
"After one year of use (the drug) produces modest weight loss of approximately five per cent," said lead researcher Cintia Curioni, at the State University of Rio de Janeiro.
该研究的负责人，里约热内卢联邦大学的Cintia Curioni说道，“使用该药一年后，使用者可达最适体重，大概减掉5%（还是5%的人减到这种程度？）[标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-07-09 17:11
医学,生命科学网